Figure 5
(A) Changes in survival in BA-model mice induced by an anti-CXCL1 antibody (n=10) or rhIL-8 (n=8) compared with RRV inoculation alone or no treatment. (B) The body weight changes corresponding to (A). (C) Changes in mouse survival induced by the anti-CXCL1 antibody in the Stattic + RRV group (n=11) compared with the Stattic + RRV group (n=10) and by Colivelin in the rhIL-8 + RRV group (n=9) compared with the rhIL-8 + RRV group (n=8). (D) The body weight changes corresponding to (B). (E) Neutrophil counts corresponding to (A) determined by immunohistochemical staining with an anti-neutrophil antibody. *P<0.05, **P<0.01, ***P<0.001. (F) Neutrophil counts for the data in (C) determined by immunohistochemical staining. *P<0.05, **P<0.01, ***P<0.001.
Administration of an anti-CXCL1 antibody or human recombinant IL-8 (rhIL-8) to BA-model mice and the effects of combining the antibody treatment with STAT3 inhibition or activation

(A) Changes in survival in BA-model mice induced by an anti-CXCL1 antibody (n=10) or rhIL-8 (n=8) compared with RRV inoculation alone or no treatment. (B) The body weight changes corresponding to (A). (C) Changes in mouse survival induced by the anti-CXCL1 antibody in the Stattic + RRV group (n=11) compared with the Stattic + RRV group (n=10) and by Colivelin in the rhIL-8 + RRV group (n=9) compared with the rhIL-8 + RRV group (n=8). (D) The body weight changes corresponding to (B). (E) Neutrophil counts corresponding to (A) determined by immunohistochemical staining with an anti-neutrophil antibody. *P<0.05, **P<0.01, ***P<0.001. (F) Neutrophil counts for the data in (C) determined by immunohistochemical staining. *P<0.05, **P<0.01, ***P<0.001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept